Safety and Efficacy of Inclisiran in Patients With Heterozygous Familial Hypercholesterolemia - Results From the Phase 3 ORION-9 Trial

导出原文传递

翻译打印收藏纠错

作者： Raal, Frederick J. ^[1] ; Ray, Kausik K. ^[2] ; Kallend, David ^[3] ; Koenig, Wolfgang ^[4] ; Wright, R. Scott ^[5] ; Leiter, Lawrence A. ^[6] ; Wijngaard, Peter L. ^[7] ; Kastelein, Johannes J., Jr. ^[8]

作者单位： Imperial Coll London, Dept Primary Care & Publ Hlth, London, England ^[1] Acad Med Ctr, Vasc Med, Amsterdam, Netherlands ^[2] Univ Toronto, Div Endocrinol & Metab, Toronto, ON, Canada ^[3] Univ Ulm, Med Ctr, Cardiol, Ulm, Germany ^[4] Medicines Co, Hlth Sci, Morristown, NJ USA ^[5] Mayo Clin, Cardiol, Rochester, MN USA ^[6] Medicines Co, Hlth Sci, Parsippany, NJ USA ^[7] Johannesburg Hosp, Endocrinol, Johannesburg, South Africa ^[8]

发布时间 2020-11-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Circulation

2019年140卷25期

E987-E987页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Safety and Efficacy of Inclisiran in Patients With Heterozygous Familial Hypercholesterolemia - Results From the Phase 3 ORION-9 Trial

Circulation

相似文献

Circulation

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Safety and Efficacy of Inclisiran in Patients With Heterozygous Familial Hypercholesterolemia - Results From the Phase 3 ORION-9 Trial

Circulation

相似文献

Circulation

相关期刊

检索历史清除